Affiliation:
1. Department of Internal Medicine University of Cincinnati Medical Center Cincinnati Ohio USA
2. Department of Pediatrics Cincinnati Children's Hospital Cincinnati Ohio USA
Abstract
AbstractBackgroundViral infections such as adenovirus (ADV), BK virus (BKV), and cytomegalovirus (CMV) after kidney transplantation negatively impact outcomes in transplant recipients despite advancements in screening and antiviral therapy. We describe our experience of using the virus‐specific T cell therapy (VSTs) in kidney transplant recipients (KTR) at our transplant center.MethodsThis is a retrospective, single center review of KTR with ADV, BKV and CMV infections between June 2021 and December 2022. These patients received third party VSTs as part of the management of infections. The immunosuppression, details of infection and outcome data were obtained from electronic medical records.ResultsTwo cases of ADV infection resolved after one infusion of VSTs. The response rate of BKV and CMV infection was not as robust with close to 50% reduction in median viral load after VSTs. Out of 23 patients, two patients developed chronic allograft nephropathy from membranoproliferative glomerulonephritis and acute rejection.ConclusionPatients that are resistant to antivirals or who have worsening viremia despite conventional management may benefit from VSTs therapy to treat underlying viral infection. Additional studies are needed to ascertain efficacy and short‐ and long‐term risks secondary to VSTs.
image
Subject
Infectious Diseases,Transplantation
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献